Patient characteristics
| . | T-cell–depleted SCT patients without EBV-LPD (n = 20) . | T-cell–depleted SCT patients with EBV-LPD (n = 6) . |
|---|---|---|
| Age, y | ||
| Mean (range) | 7.3 (1-16) | 6.6 (1-13) |
| Diagnosis, n | ||
| ALL CR1 | 3 | |
| ALL CR2 | 4 | 1 |
| AML CR1 | 1 | 1 |
| FEL | 2 | 1 |
| SAA | 1 | 2 |
| Fanconi | 1 | |
| MLD | 1 | |
| X-ALD | 2 | |
| Hurler-Scheie | 1 | |
| SCID | 1 | 1 |
| JMML/CML | 2 | |
| MDS | 1 | |
| Donor type, n | ||
| MUD | 12 | 4 |
| Haplo | 8 | 2 |
| Conditioning includes, n | ||
| ATG | 3 | 1 |
| Campath-1H | 2 | 1 |
| ATG + anti-LFA-1 | 3 | 2 |
| Campath-1H + anti-LFA-1 | 11 | 1 |
| Positive EBV serology, n | ||
| D/R | 20/14 | 6/3 |
| Stem cell graft preparation, n | ||
| CD34+ selection | 7 | 2 |
| T and B immunorosetting | 12 | 3 |
| Other* | 1 | 1 |
| . | T-cell–depleted SCT patients without EBV-LPD (n = 20) . | T-cell–depleted SCT patients with EBV-LPD (n = 6) . |
|---|---|---|
| Age, y | ||
| Mean (range) | 7.3 (1-16) | 6.6 (1-13) |
| Diagnosis, n | ||
| ALL CR1 | 3 | |
| ALL CR2 | 4 | 1 |
| AML CR1 | 1 | 1 |
| FEL | 2 | 1 |
| SAA | 1 | 2 |
| Fanconi | 1 | |
| MLD | 1 | |
| X-ALD | 2 | |
| Hurler-Scheie | 1 | |
| SCID | 1 | 1 |
| JMML/CML | 2 | |
| MDS | 1 | |
| Donor type, n | ||
| MUD | 12 | 4 |
| Haplo | 8 | 2 |
| Conditioning includes, n | ||
| ATG | 3 | 1 |
| Campath-1H | 2 | 1 |
| ATG + anti-LFA-1 | 3 | 2 |
| Campath-1H + anti-LFA-1 | 11 | 1 |
| Positive EBV serology, n | ||
| D/R | 20/14 | 6/3 |
| Stem cell graft preparation, n | ||
| CD34+ selection | 7 | 2 |
| T and B immunorosetting | 12 | 3 |
| Other* | 1 | 1 |
ALL CR1 indicates acute lymphoblastic leukemia first remission; AML CR1, acute myeloblastic leukemia first remission; FEL, familial erythrophagocytic lymphhistiocytosis; SAA, severe aplastic leukemia; MLD, metachromatic leukodystrophy; X-ALD, X-linked adrenoleukodystrophy; JMML/CML, juvenile myelomonocytic leukemia/chronic myeloid leukemia; MDS, myelodysplastic syndrome; LFA-1, lymphocyte junction-associated antigen type 1; D/R, donor recipient.
Campath-1G in the bag and E-rosetting, respectively.